[Kombipek in the therapy of patients with broncho-obstructive lung diseases]. / "Kombipék" v terapii bol'nykh bronkhoobstruktivnymi zabolevaniiami legkikh.

Bronchodilator combipek of Russian produce was tested in 43 patients with bronchial asthma of various severity. Combipek contains 200 mg of theophylline and 8 mg of salbutamol. Pharmacokinetics of the drug was evaluated after a single administration and upon obtaining equilibrium concentration. Functional and clinical evidence showed a prolonged effect and safety of the drug in long-term treatment of bronchial asthma. Adverse effects emerged in 13 (30.2%) patients. They were typical for theophylline and beta 2-adrenostimulators. Combipek is advocated as a treatment of choice in patients with nocturnal asphyxia, in those who can hardly tolerate large doses of theophylline and beta 2-adrenostimulators.

[Functional status of the adrenal cortex in patients with multiple sclerosis]. / Funktsional'noe sostoianie kory nadpochechnikov u bol'nykh rasseiannym sklerozom.

The spectrum of daily urine C21-corticosteroids was examined in 50 patients by thin-layer chromatography on silica gel. There were 28 men and 22 women aged 16--50 years with a disease standing from 1 to 26 years. Twenty-two healthy persons of the same age formed the control group. Appropriate indices were calculated to have a deeper insight into adrenocortical function. The dependence of gluco- and promineralocorticoid activity and of corticosteroid biosynthesis and metabolism on the disease course and acuity was revealed. The data obtained made it possible to elaborate the most rational treatment tactics in patients with disseminated sclerosis and to define the opportunities of glucocorticoid use taking into consideration the adrenocortical response to the pathological process.